Search research articles
Contact Us
Filters
Showing results (91-100 of 117) with videos related to
Page
of 12
Sort By:
Liver International : Official Journal of the International Association for the Study of the Liver
|
June 25, 2025
Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre Study
Takeshi Hatanaka, Yutaka Yata, Atsushi Hiraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
November 11, 2024
Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice
Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, et al.
Liver Cancer
|
October 9, 2025
Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin-Based Tumor Marker Score for First-Line Immunotherapy Selection in Hepatocellular Carcinoma
Kazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Oncology
|
August 10, 2025
Limited Prognostic Impact of Sustained Virologic Response on Atezolizumab plus Bevacizumab Therapy for HCV-Related Unresectable Hepatocellular Carcinoma
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
September 6, 2025
Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis
Takeshi Hatanaka, Yutaka Yata, Atsushi Hiraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
August 6, 2025
Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis
Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.
Journal of Gastroenterology
|
August 20, 2025
Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Cancer Medicine
|
February 15, 2026
Three-Year Long-Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Journal of Gastroenterology and Hepatology
|
May 23, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial
Tomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
April 10, 2026
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab
Kazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 117) with videos related to
Sort By:
Page
of 12
Liver International : Official Journal of the International Association for the Study of the Liver
|
June 25, 2025
Clinical Impact of Serum CRP Levels on Advanced HCC Treated With Durvalumab and Tremelimumab: A Multicentre Study
Takeshi Hatanaka, Yutaka Yata, Atsushi Hiraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
November 11, 2024
Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice
Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, et al.
Liver Cancer
|
October 9, 2025
Alpha-Fetoprotein and Des-Gamma-Carboxy Prothrombin-Based Tumor Marker Score for First-Line Immunotherapy Selection in Hepatocellular Carcinoma
Kazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Oncology
|
August 10, 2025
Limited Prognostic Impact of Sustained Virologic Response on Atezolizumab plus Bevacizumab Therapy for HCV-Related Unresectable Hepatocellular Carcinoma
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
September 6, 2025
Efficacy and Safety of Durvalumab Plus Tremelimumab in Hepatocellular Carcinoma Patients With Portal Vein Thrombosis and High Tumor Burden: A Multicenter Retrospective Analysis
Takeshi Hatanaka, Yutaka Yata, Atsushi Hiraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
August 6, 2025
Safety and Efficacy of Durvalumab Plus Tremelimumab in Older Individuals With Unresectable Hepatocellular Carcinoma: A Multicenter Analysis
Tomomitsu Matono, Toshifumi Tada, Takashi Kumada, et al.
Journal of Gastroenterology
|
August 20, 2025
Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Cancer Medicine
|
February 15, 2026
Three-Year Long-Term Outcomes in Patients With Unresectable Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab Treatment in Clinical Practice
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Journal of Gastroenterology and Hepatology
|
May 23, 2026
Outcomes of Patients With Hepatocellular Carcinoma Treated With Durvalumab Plus Tremelimumab in Real-World Clinical Practice Who Met or Did Not Meet the Inclusion Criteria for the Phase 3 HIMALAYA Trial
Tomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology
|
April 10, 2026
Impact of Intrahepatic Tumor Burden on Outcomes in Patients With Hepatocellular Carcinoma With Extrahepatic Metastases Treated With Atezolizumab Plus Bevacizumab
Kazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Page
of 12